The US Food and Drug Administration (FDA ... Marstacimab is Pfizer's second hemophilia approval in 2024. FDA approved the company's hemophilia B gene therapy fidanacogene elaparvovec (Beqvez ...

Earlier this year, FDA approved Pfizer’s Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or ...

Pfizer PFE announced that the FDA has approved its subcutaneously administered drug marstacimab for treating certain hemophilia patients. The drug will be marketed under the trade name Hympavzi.

Hympavzi, made by Pfizer, is the first antitissue-factor pathway inhibitor to be approved for the blood-clotting disorder, as well as the first hemophilia ... of the FDA's Center for Drug ...

Pfizer Inc. has won regulatory approval for its hympavzi drug ... from hemophilia B, as they have fewer options than are available for hemophilia A. Ciara Linnane is MarketWatch's investing ...

(RTTNews) - Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved ... patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency ...

FDA approves Pfizer’s Hympavzi for routine prophylaxis in hemophilia A and B patients, offering a once-weekly dosing via auto-injector pen. Phase 3 trial showed Hympavzi reduced bleeding rates ...

Hympavzi is the first anti-tissue factor pathway inhibitor therapy to be approved in the United States for routine prophylaxis of bleeding in patients with hemophilia A or B without inhibitors. The ...

HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis and on-demand treatment in eligible patients with hemophilia A or ...